PFE's non-oncology portfolio draws focus in Q2, with strength in Vyndaqel and Nurtec offsetting some vaccine softness.

Respiratory syncytial virus (RSV) poses a significant, often overlooked, risk for serious cardiovascular complications in ...

The CDC recently updated RSV vaccine recommendations to include certain adults aged 50 and up. When is the best time to get ...

A new respiratory syncytial virus vaccine to protect infants from severe illness is available in South Africa’s private sector, but not yet in public clinics. The country’s advisory group on ...

The COVID booster currently available is based on the JN.1 subvariant. Nimbus is a direct descendant of JN.1 – as is another ...

Public health minister Jenni Minto said the jab would be available for babies born before 32 weeks to protect them over the ...